The Federal Drug Administration (FDA) has approved gadolinium for use as a contrast agent in Magnetic Resonance Imaging (MRI). As a contrast agent, gadolinium allows MRIs to generate a clearer picture of the body’s organs and tissues.

Although MRIs can be performed without the contrast agent, the use of contrast agents allows doctors to better diagnose patients. Currently, gadolinium is the only FDA-approved contrast agent.

Gadolinium has been cited as the potential cause for patients contracting Nephrogenic Systemic Fibrosis (NSF), when the patient underwent an MRI that used gadolinium. Currently, the FDA has not established an official causal link between gadolinium and NSF, but is currently doing research to evaluate whether a causal link exists.

If you or anyone you know suffers from NSF and underwent an MRI with the gadolinium-contrast agent, please contact the NSF lawyers of Williams Kherkher at 800-761-3187.